Trial Profile
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms DECISION
- Sponsors Bayer; Bayer HealthCare; Bayer Yakuhin; Onyx Pharmaceuticals
- 26 Sep 2019 Results of a retrospective, exploratory biomarker analysis assessing prognostic biomarkers for disease outcome and predictive biomarkers for sorafenib treatment, published in the Clinical Cancer Research
- 02 Dec 2017 This trial was completed in Sweden (end date: 30/08/2017), according to European Clinical Trials Database.
- 02 Dec 2017 This trial was completed in Netherlands, according to European Clinical Trials Database.